Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
- Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
- Drug Approvals
- Clinical Trial Calendar

Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard

Crypto
Cryptocurrency
Blockchain

Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies

Politics
US
World
White House
Elections
General News

Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard

Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health

Slide Shows

Entertainment
Top Stories
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre

Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services

Premium
Intelligent Investor
Biotech Investor NEW
Login

Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us

Business
Corp. News
- Latest Headlines
- Biotech
- Investors
- Stock Alerts
- IPOs
- M&A
Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
Corp. Calendars
Earnings Calendar
FDA Calendars
- Drug Approvals
- Clinical Trial Calendar
Ratings Changes
Economy
- US
- Europe
- Asia
- Global
- Economic Calendar
- Economic Scorecard
Crypto
- Cryptocurrency
- Blockchain
Markets
Market News
Politics
- US
- World
- White House
- Elections
- General News
Forex
Health
Health News
Slide Shows
Entertainment
Entertainment News
- Top Stories
Music News
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre
Content Licensing
Premium
More

Outlook Therapeutics, Inc. (OTLK)

Outlook Therapeutics' BLA Resubmission For ONS-5010 Accepted By FDA For Wet AMD Review 6/16/2026 9:30:53 AM

3 Stocks To Watch Today: SLBT, OTLK, BIOA 6/16/2026 9:16:57 AM

Outlook Therapeutics Resubmits BLA For ONS-5010 In Wet AMD; FDA Sets July 2026 Review Date 6/16/2026 8:14:10 AM

Outlook Resubmits BLA To FDA For LYTENAVA In Treating Macular Degeneration; Stock UP 6/1/2026 12:07:16 PM

Outlook Therapeutics Resubmits BLA To FDA For ONS-5010/LYTENAVA In Wet AMD 6/1/2026 8:49:57 AM

Outlook Therapeutics Prices $5 Million Registered Direct Offering 5/29/2026 2:35:53 AM

Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest 5/29/2026 2:27:52 AM

Will Outlook Therapeutics' Wet AMD Drug Cross The FDA Finish Line On Its 4th Attempt? 5/27/2026 10:38:38 AM

Top Biotech Gainers: CODX Soars On Ebola Assay Progress, NRXP Nears FDA Decision, NVAX On Watch 5/27/2026 3:54:17 AM

Outlook Therapeutics Stock Climbs 38% After Winning FDA Appeal For NAMD Therapy 5/26/2026 9:46:01 AM

Outlook Therapeutics Wins FDA Appeal For NAMD Therapy; Stock Up 5/26/2026 8:54:00 AM

Outlook Therapeutics Q2 Net Loss Narrows; Expects FDA Decision For LYTENAVA In May 2026 5/18/2026 1:53:08 AM

Outlook Completes FDR Meeting With FDA For LYTENAVA In Treating Macular Degeneration 4/21/2026 11:24:20 AM

FDA Accepts Outlook Therapeutics' FDRR To Resolve ONS-5010/LYTENAVA Regulatory Issues; Stock Up 4/8/2026 3:53:20 AM

Outlook Plunges Over 48% After Pricing $5 Mln Offering Of Shares And Warrants; Marks New 52-week Low 3/24/2026 10:22:19 AM

Outlook Therapeutics Hits 52-Week Low As It Launches Proposed Public Offering 3/24/2026 2:34:08 AM

Older Articles

Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us | Contact Us | Privacy | Sitemap